



Aggregate Net Sales and Payment Information

The table below sets out aggregate information on:

- Net sales for quarters 1-4 of calendar year 2013;
- Net sales and payments for quarter 1 of calendar year 2014.

There are two columns for net sales information:

- Net sales subject to branded medicines bill growth calculation (Measured Spend)¹;
- Net sales covered by the PPRS Payment².

The table sets out information held on the Department of Health PPRS Operations database on 18 June 2014. The aggregate payments total is the total of payments actually received by the Department at that date.

Please note that the data is subject to correction of errors and has not yet been audited. The audit and reconciliation arrangements are set out in paragraphs 6.24-6.30 and 6.37-6.40 of the PPRS.

Our intention is:

- At each quarterly publication point, to publish an update of all the previous quarters' figures until the point at which audited data is published for the year concerned.
- Following the receipt of complete audited information, to publish annual audited data. Once annual audited data has been published there would be no further updates of those quarters³.
- To publish any revisions to data following the 2016 reconciliation exercise.
- To retain each pdf published on the website until the end of the PPRS to provide an audit trail of changes.

	Aggregate Net Sales Subject to Medicines Bill Growth Calculation (Measured Spend)	Aggregate Net Sales Covered by the PPRS Payment	Aggregate Payments Received by the Department of Health
2013 Q1	£1,863M	£1,863M	N/A
2013 Q2	£1,937M	£1,937M	N/A
2013 Q3	£2,006M	£2,006M	N/A
2013 Q4	£2,145M	£2,145M	N/A
2014 Q1	£1,975M	£1,973M	£74M

¹Measured spend is defined in paragraph 6.6 of the PPRS and means the spend which is controlled by the PPRS Payments mechanism. It includes sales of new products.

²Sales covered by the PPRS Payment is defined at paragraph 6.7 of the PPRS. The percentage payment applies to these sales, which exclude sales of new products. Sales of new products are included in the calculation of the overall sum to be repaid across all member companies. However, products with a new active substance designation that are introduced after 31 December 2013 are excluded from the sales used to calculate the payment by each company.

³Companies are required to provide audited annual data nine months after the end of their financial year. For 2013 final audited data would be published in November 2015 once the audited returns for companies with financial years ending November have been received and collated.